Watson for Sale, What We’ve Learned from Our Time Together

March 8, 2021

 – Episode #


Watson is for sale, what happened?  Could it have been avoided?

Today an object lesson on how not to enter healthcare.

The Wall Street Journal says Big Blue is pondering ways it might off-load the healthcare AI subsidiary, and IBM CEO Arvind Krishna has already signaled a ”maniacal focus” on hybrid cloud development.

The division has seen some major milestones in the decade since Watson first wowed the world with its much-hyped Jeopardy! win in 2011 and the announcement soon after that the technology would be applied to healthcare. Then specific use cases began to emerge. Big Blue had big plans for what it might accomplish.

Since then, the Watson business has grown substantially, through a series of targeted, multi-billion-dollar acquisitions: Merge Healthcare for imaging, Phytel and Explorsys for population health and Truven Health Analytics for value-based care.

But there have also been some high-profile setbacks along the way.

If you are going to enter a space like Deion Sanders, you better have game like Deion Sanders.  IBM entered healthcare loud and proud with bold claims to turn their Jeopardy win into cancer moonshots and diagnostic transformation.  What went wrong?  Data.

Watson, like most AI is hungry for data.  “Feed me Seymore” is the cry of AI tools, much like the alien plant from  Little Shop of Horrors.  But our data was messy and didn’t satisfy Watson the way it was intended.

What are your thoughts?


More Recent Episodes

Share this clip:

Share on linkedin
Share on twitter
Share on facebook
Share on email

Today's Show Sponsor

Want to tune in on your favorite listening platform? Don't forget to subscribe!

Thank You to Our Show Sponsors

Amplify great thinking to propel healthcare forward and raise up the next generation of health leaders.

© Copyright 2021 Health Lyrics All rights reserved